MedImmune Delays Numax BLA Pending Additional RSV Trial Data
Company hopes data from a second Phase III trial, due at summer’s end, will make the application more attractive to FDA.
Company hopes data from a second Phase III trial, due at summer’s end, will make the application more attractive to FDA.